Video

Case Study: HER2-Positive Oligometastatic Breast Cancer

For High-Definition, Click

In a case-based discussion, moderator Adam M. Brufsky, MD, PhD, describes a 40-year-old woman with a 2 cm mass in her left breast and a single 2 cm metastatic liver lesion. A biopsy of the left breast reveals the tumor is estrogen receptor (ER)-positive and HER2-positive. A biopsy of the liver indicates that it is HER2-positive and ER-negative.

The majority of the panel agrees that a combination regimen of docetaxel, trastuzumab, and pertuzumab (THP) is ideal for this scenario. Joyce A. O’Shaughnessy, MD, suggests that carboplatin should also be administered, since it appears to be oligometastatic disease that could be amenable to a curative therapeutic strategy. Moreover, the addition of a DNA damaging agent, like carboplatin, appears to be beneficial in the setting of ER-negative disease, O’Shaughnessy notes.

Depending on the response to the combination therapy, a hepatic metastasectomy could be performed following the completion of treatment, believes Hope S. Rugo, MD. An optimal strategy may include treatment with the 4-drug combination followed by docetaxel plus trastuzumab or trastuzumab plus pertuzumab with an assessment of the metastatic site at 6 to 12 months, suggests Brufsky. At this point, if the lesion is still present, metastasectomy is a reasonable option.

Related Videos
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the sensitivity and specificity of Rapid Lung NGS for biomarker testing in NSCLC.